Search Results - "Reardon, Josh"

Biweekly cisplatin (C) and gemcitabine (G) in patients (pts) with advanced biliary tract cancer (ABTC): A retrospective analysis by Ahn, Daniel H., Reardon, Josh, Ahn, Chul, Bupathi, Manojkumar, Ciombor, Kristen Keon, Wu, Christina Sing-Ying, Bekaii-Saab, Tanios S.

“…Abstract only 434 Background: Based on the ABC 02 trial, standard therapy for ABTC is CG for up to 8 cycles. However, a recent abstract (Doherty et al, ASCO…”
Get full text

Biweekly cisplatin and gemcitabine in patients with advanced biliary tract cancer by Ahn, Daniel H., Reardon, Josh, Ahn, Chul W., Bupathi, Manojkumar, Mikhail, Sameh, Wu, Christina Sing‐Ying, Bekaii‐Saab, Tanios

“…Treatment with cisplatin and gemcitabine demonstrates a survival benefit in patients with advanced biliary tract cancer (ABTC). However, the weekly…”
Get full text

Irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): A single institution experience by Bupathi, Manojkumar, Ahn, Daniel H., Ciombor, Kristen Keon, Wu, Christina Sing-Ying, Mikhail, Sameh, Goldberg, Richard M., Noonan, Anne M., Stephens, Julie, Reardon, Josh, Hays, John L., Bekaii-Saab, Tanios S.

“…Abstract only 215 Background: Pancreatic adenocarcinoma is the fourth leading cause of cancer with a very dismal prognosis. Recently, MM-398 (nanoliposomal…”
Get full text

Tolerability and efficacy of modified FOLFIRINOX (mFOLFIRINOX) in patients with borderline-resectable pancreatic cancer (BRPC) and locally advanced unresectable pancreatic cancer (LAURPC) by Blazer, Marlo A., Wu, Christina Sing-Ying, Goldberg, Richard M., Phillips, Gary S., Schmidt, Carl Richard, Muscarella, Peter, El-Dika, Samer S, Walker, Jon P, Krishna, Somashekar Gopala, Groce, J. Royce, Wuthrick, Evan John, Williams, Terence M, Efries, David, Smith, Yahna T., Mathey, Kris, Wagner, Mandy, Reardon, Josh, Ellison, Edwin Christopher, Bloomston, Mark, Bekaii-Saab, Tanios S.

“…Abstract only 275 Background: FOLFIRINOX exhibits a meaningful improvement in outcome measures in metastatic pancreatic cancer, making it an interesting…”
Get full text